Physician profile
Mohammad Shakir
NPI 1932342102
$3,137.67
in general payments reported to CMS, 2019-2025
25 companies · $734 in 2025
The $734 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $57.30 · 2021: $290 · 2022: $205 · 2023: $699 · 2024: $730 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $719.41 | 2019-2025 | Lifevest |
| Amgen INC. | $423.94 | 2019-2025 | Repatha, Repatha |
| Aop Health US, LLC | $403.95 | 2025 | Rapiblyk |
| Novartis Pharmaceuticals Corporation | $295.34 | 2022-2025 | |
| Pfizer INC. | $251.66 | 2019-2025 | |
| Edwards Lifesciences Corporation | $180.68 | 2023 | Pascal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.96 | 2022-2024 | Jardiance |
| Inspire Medical Systems, INC. | $126.45 | 2023-2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $95.14 | 2021-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $89.23 | 2022-2023 | Verquvo |
| Boston Scientific Corporation | $55.38 | 2024 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $49.06 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $44.90 | 2021-2025 | Camzyos |
| Cardiovascular Systems INC. | $38.19 | 2019 | |
| Chiesi USA, INC. | $31.86 | 2023 | Cleviprex, Kengreal |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $24.73 | 2025 | Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $24.69 | 2023 | |
| Abbott Laboratories | $23.39 | 2022 | |
| Novo Nordisk INC | $23.06 | 2020 | |
| Lantheus Medical Imaging, INC. | $19.92 | 2025 | |
| Esperion Therapeutics, INC. | $17.99 | 2024 | Nexletol |
| Atricure, INC. | $17.56 | 2024 | |
| Cordis US Corp. | $16.50 | 2024 | Mynx Venous Vcd |
| Kiniksa Pharmaceuticals International, Plc | $15.98 | 2024 | Arcalyst |
| Cvrx, INC. | $12.70 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Shakir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.